1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Indiana >
  6. Novartis Acquires Endocyte

M&A Deal Summary

Novartis Acquires Endocyte

On October 18, 2018, Novartis acquired life science company Endocyte for 2.1B USD

Acquisition Highlights
  • This is Novartis’ 15th transaction in the Life Science sector.
  • This is Novartis’ 7th largest (disclosed) transaction.
  • This is Novartis’ 15th transaction in the United States.
  • This is Novartis’ 1st transaction in Indiana.

M&A Deal Summary
Date 2018-10-18
Target Endocyte
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition
Deal Value 2.1B USD

Target

Endocyte

West Lafayette, Indiana, United States
Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company’s agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2024)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 18 of 36
Sector: Life Science M&A 15 of 30
Type: Add-on Acquisition M&A Deals 16 of 30
State: Indiana M&A 1 of 1
Country: United States M&A 15 of 28
Year: 2018 M&A 2 of 2
Size (of disclosed) 7 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-04-09 AveXis

Dallas, Texas, United States

AveXis is a clinic-ready, synthetic biology platform company. AveXis has several ongoing clinical studies for the treatment of SMA, an inherited neurodegenerative disease caused by a defect in a single gene, the survival motor neuron (SMN1). The lead AveXis gene therapy candidate, AVXS-101, has highly compelling clinical data in treating SMA Type 1, which is the number one genetic cause of death in infants, where 9 out of 10 infants do not live to their second birthday or are permanently ventilator dependent. It is estimated that one out of every 6,000-10,000 children born is affected by some form of SMA.

Buy $8.7B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-12 Novartis AG - Farydak

Basel, Switzerland

Farydak is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs at nanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins, an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation.

Sell -
Mergr

Solution for

Product

Company

Legal